Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
EBEmergent BioSolutions Inc. logo

Emergent BioSolutions Inc. (EBS)

New York Stock Exchange · Currency in USD
$6.23 ▲ +0.00 (+0.00%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$6.23
Open
$6.18
Day's Range
$6.02 – $6.25
52 Week Range
$4.36 – $14.06
Volume
727,330
Avg. Volume
1,115,882
Market Cap
$319.43M
Beta (5Y Monthly)
2.29
PE Ratio (TTM)
--
EPS (TTM)
-$3.43
Earnings Date
Nov 2, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$10.00

Profile: Emergent BioSolutions Inc.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
900
CEO
Joseph C. Papa Jr.

Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox.

Earnings

Next report: Mon, Nov 2, 2026
EPS estimate -$0.37 · Revenue est. $123.22M
DateEst.Actual
Aug 5, 2026-$0.09$0.60Beat
Apr 30, 2026-$0.25$0.21Beat
Feb 26, 2026$0.11-$0.43Miss
Oct 29, 2025-$0.12$1.06Beat
Aug 6, 2025-$0.26$0.16Beat
May 7, 2025$0.49$0.71Beat

Analyst view

Consensus price target
$10.00 ▲ +60.5%
Range $10.00 – $10.00
Rating: Buy
Buy 73% · Hold 20% · Sell 7%

Get free alerts on EBS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.